Cryo-trojan mesenchymal stem cells as non-living tumor-homing supercarriers for enhanced drug delivery and immune activation in prostate cancer
CT-MTX represents a novel, non-proliferative drug delivery platform that combines the tumor-homing capacity of MSCs with enhanced safety and controlled release, inducing ICDs for prostate cancer and other immunologically "cold" tumors to improve immune infiltration.
Authors
- Xianfang Rong (ORCID: https://orcid.org/0009-0002-5495-8305)
- Fuqiang Zhang (ORCID: https://orcid.org/0000-0002-2627-5876)
- Chengran Wang (ORCID: https://orcid.org/0009-0003-2120-9452)
- Xupeng Mu
- Jinlan Jiang (ORCID: https://orcid.org/0000-0001-5116-875X)
Institutions
- Union Hospital (HK)
- Union Hospital (CN)
Publication Details
- Journal
- Materials Today Bio
- Published
- 2025-03-12
- DOI
- https://doi.org/10.1016/j.mtbio.2025.101650
- Citations
- 5
- Primary Topic
- Extracellular vesicles in disease
- Type
- article
- Field-Weighted Citation Impact
- 4.03
Funders
- National Natural Science Foundation of China
- Jilin Scientific and Technological Development Program